SCLL stock performance?

Pink Sheets: Stem Cell Innovations, Inc. (SCLL) financial news, and detailed stock charts

This company symbol is outdated. Results displayed are archieved for your information

Stem Cell Innovations, Inc. (SCLL/SCLL.PK) Penny Stock Summary:

Stem Cell Innovations, Inc., a cell biology company, engages in the development and production of its pluripotent stem cells in the United States. Its products include ACTIVTox, which measures various aspects of liver toxicity; and PREDICTIVTox, a database of information from compounds that allows chemists to organize and view the data to make structural decisions about the molecules. The company is also developing differentiated cell lines from its proprietary human pluripotent cells, adding to the cell types that may be used as a screen for drug discovery and toxicity, as well as for cellular replacement therapy. In addition, it develops its C3A human liver cell line for the production of human serum proteins, including the clotting factors used by hemophiliacs to allow their blood to clot; and develops other products, such as production of antibodies or the treatment of various diseases by in vivo cellular replacement therapy or in ex vivo applications, such as liver assist devices. Further, Stem Cell Innovations offers contract research and testing, and consulting services. Stem Cell Innovations, Inc. was formerly known as Interferon Sciences, Inc. The company was founded in 1980 and is based in Houston, Texas.
www.standardcharteredleasing.com
Founded in 1993
Last 5.25 PKR
Change Today 0.00 / 0.00%
Volume 10.5K
As of 5:53 AM 11/8/12 All times are local (Market data is delayed by at least 15 minutes).

standard charted leasing ltd (SCLL) Snapshot

Open
5.25
Previous Close
5.25
Day High
5.25
Day Low
5.10
52 Week High
09/19/12 - 6.64
52 Week Low
01/24/12 - 2.05
Market Cap
513.6M
Average Volume 10 Days
5.6K
EPS TTM
0.78
Shares Outstanding
97.8M
EX-Date
10/11/12
P/E TM
6.7x
Dividend
0.80
Dividend Yield
15.24%
SCLL:PA Historical Stock Quote
SCLL:PA Advanced Stock Chart

Related News

No related news articles were found.

standard charted leasing ltd (SCLL) Related News

No Related News Found

standard charted leasing ltd (SCLL) Key Developments

Standard Chartered Leasing Ltd., Board Meeting, Oct 19, 2012

Standard Chartered Leasing Ltd., Board Meeting, Oct 19, 2012., at 10:00 Pakistan Standard Time. Agenda: To consider and approve quarterly accounts for the quarter ended September 30, 2012.

Standard Chartered Leasing Ltd. to Report Q1, 2013 Results on Oct 19, 2012

Standard Chartered Leasing Ltd. announced that they will report Q1, 2013 results on Oct 19, 2012

Standard Chartered Leasing Ltd. Reports Earnings Results for the Year Ended June 30, 2012; Approves Final Cash Dividend for the Year Ended June 30, 2012

Standard Chartered Leasing Ltd. reported earnings results for the year ended June 30, 2012. For the year, the company reported revenues of PKR 449,593,317 compared to PKR 306,876,467 a year ago. Profit before taxation was PKR 177,859,497 compared to PKR 117,344,932 a year ago. Profit after taxation was PKR 97,856,303 or PKR 1.00 per share compared to PKR 76,274,206 or PKR 0.78 per share a year ago. The company approved a final cash dividend of PKR 0.80 per share for the year ended June 30, 2012 compared to PKR 0.5 per share a year ago.

Stem Cell Innovations, Inc. financial resources

otc, otcbb, pinksheet, SCLL, ob Stem Cell Innovations, Inc.

Most Popular on

The Polls Shift Toward Obama
Trump: 'No Regrets' Over Twitter Meltdown
Base-Jumping Stunt Goes Horribly Wrong
Zuckerberg's Dorm Mate: $400M Mistake and No Regrets
Genius: The Nickelback Story
More News
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLL:PA 5.25 PKR 0.00

SCLL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCLL.
 

Industry Analysis

SCLL

Industry Average

Valuation SCLL Industry Range
Price/Earnings 5.2x
Price/Sales 1.0x
Price/Book 0.6x
Price/Cash Flow 5.2x
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

  • President and CEO
    New Windsor, NY | Emeriti Retirement Health Solutions
    Posted: Nov 06
  • Product Manager - Consumer Team
    San Francisco, CA | Yelp
    Posted: Oct 26
  • Minnesota | UnitedHealth Group
    Posted: Sep 25
  • Wilmington, DE | Farmers Insurance Group
    Posted: Nov 10
Simply Hired

Sponsored Links

Pink Sheets: Archieved Financial News About Stem Cell Innovations, Inc.

Stem Cell Innovations to Provide Research and Assay Services to Agennix.

Quote: Kelly, PhD, CEO of Stem Cell Innovations. "Our C3A cells provide a reliable and reproducible foundation on which to base the talactoferrin assays."  In addition to the talactoferrin assays, SCLL will provide other research and cell culture services to Agennix. About AgennixAgennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients.  The Company's most a...
Read article

Stem Cell Innovations to Provide Research and Assay Services to Agennix.

Quote: Kelly, PhD, CEO of Stem Cell Innovations. "Our C3A cells provide a reliable and reproducible foundation on which to base the talactoferrin assays."  In addition to the talactoferrin assays, SCLL will provide other research and cell culture services to Agennix. About AgennixAgennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients.  The Company's most a...
Read article

STEM CELL INNOVATIONS, INC. Files SEC form 8-K, Other Events

Quote: Item 8.01 Other Events. Stem Cell Innovations, Inc., (SCLL.PK) wishes to update its shareholders on various aspects of the company over the past year. Our human embryonic germ cell technology has matured substantially. This work was significantly more difficult than originally anticipated but has resulted in a series of interesting and useful observations that will fill in several missing pieces in human stem cell biology. These observations are currently being finalized and assembled into a fo...
Read article

STEM CELL INNOVATIONS, INC. Files SEC form 8-K, Regulation FD Disclosure

Quote: 2009, Stem Cell Innovations, Inc. (the "Company"). entered into an agreement with Margie Chassman ("Chassman") and Alpha Capital Anstalt ("Alpha") pursuant to which Chassman agreed to provide $500,000 of financing to the Company over a six-month period commencing upon approval by the Company's stockholders of amendments to the Company's Certificate of Incorporation (the "Amendments") reducing the par value of the Company's common stock from $.01 per share ...
Read article

STEM CELL INNOVATIONS, INC. Files SEC form 8-K, Regulation FD Disclosure

Quote: 2008, Stem Cell Innovations, Inc. (the "Company") raised $300,000 through the issuance to Alpha Capital Anstalt ("Alpha"), an existing stockholder and noteholder of the Company, of a secured convertible note. The convertible note, due December 31, 2009, is in the principal amount of $300,000, bears interest at the rate of 15% per annum, is secured by all the assets of the Company and its subsidiaries, Amphioxus Cell Technologies, Inc. and ACTIVTox Laboratories, Inc. It is con...
Read article

You can still leave a comment about Stem Cell Innovations, Inc. SCLL/SCLL.PK

Besides Stem Cell Innovations, Inc.'s Penny Stock there is more great Microcap and Stock Market information available at Realpennies.com